Rifaximin 550 MG Oral Tablet [XIFAXAN] for Colicky Pain

Phase-Based Progress Estimates
Wake Forest University Health Sciences, Winston-Salem, NC
Colicky Pain+3 More
Rifaximin 550 MG Oral Tablet [XIFAXAN] - Drug
Any Age
All Sexes
What conditions do you have?

Study Summary

This trial is investigating whether the antibiotic rifaximin can help with gastrointestinal symptoms in people with cystic fibrosis. Rifaximin 550 MG Oral Tablet [XIFAXAN] is used to treat Colicky Pain. Rifaximin 550 MG Oral Tablet [XIFAXAN] was previously approved by the FDA for a different condition.

Eligible Conditions

  • Colicky Pain
  • Small Bowel Diseases
  • Cystic Fibrosis

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 42 days

42 days
Improved ePROS scores
Two weeks
Rifaximin Treatment Group Improvement of Symptoms

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

2 Treatment Groups

1 of 2
1 of 2
Experimental Treatment
Non-Treatment Group

100 Total Participants · 2 Treatment Groups

Primary Treatment: Rifaximin 550 MG Oral Tablet [XIFAXAN] · Has Placebo Group · Phase 2 & 3

Experimental Group · 1 Intervention: Rifaximin 550 MG Oral Tablet [XIFAXAN] · Intervention Types: Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 42 days
Closest Location: Wake Forest University Health Sciences · Winston-Salem, NC
2008First Recorded Clinical Trial
0 TrialsResearching Colicky Pain
426 CompletedClinical Trials

Who is running the clinical trial?

University of MinnesotaOTHER
1,229 Previous Clinical Trials
1,455,032 Total Patients Enrolled
University of Texas Southwestern Medical CenterOTHER
936 Previous Clinical Trials
594,166 Total Patients Enrolled
Emory UniversityOTHER
1,498 Previous Clinical Trials
2,666,227 Total Patients Enrolled
Wake Forest University Health SciencesLead Sponsor
1,102 Previous Clinical Trials
1,129,135 Total Patients Enrolled
Baha Moshiree, MDPrincipal InvestigatorWake Forest University Health Sciences

Eligibility Criteria

Age Any Age · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are enrolled in the CF registry.
You are at least 12 years old and weigh at least 30 kilograms (~66.15 lbs).
You are able to provide informed consent.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.